CA-TRADESHIFT
10.2.2020 15:02:12 CET | Business Wire | Press release
Tradeshift, the leader in supply chain payments and marketplaces, has announced the addition of four new hires hailing from Microsoft, Ariba, SAP and Oracle. On the heels of Tradeshift’s latest funding news, in which the company announced $240 million in funding, the company welcomes these seasoned veterans to help the company reach its strategic goals for 2020.
The four new hires represent deep experience in a range of business leadership initiatives including network, product and sales. The roles include:
Janet Heppner-Jones, VP of North America Sales : Heppner-Jones has an impressive background in digital solutions and SaaS sales leadership, most recently leading the America's sales team at Baker Hughes. Her diverse background has provided her with global executive responsibilities in many multinational companies across many business functions, including SAP, ABB, Dassault Systems, and Ariba. Heppner-Jones began her career as a Sales Representative with IBM where she earned the prestigious Eagle Award (top 1% of the sales force). At Tradeshift, Heppner-Jones will continue and accelerate the 60 percent growth rate, increase deal size, and work with partners in North America.
Tony Alvarez, VP of Network : Alvarez will be responsible for Tradeshift seller onboarding, GMV growth, and the Tradeshift early payment and Marketplace offerings. Prior to joining, Alvarez spent 10 years with SAP Ariba serving in several senior leadership positions in the commercial and operational functions, most recently serving as SVP of Ariba Business Network Solutions. He has experience in large deal negotiations, network monetization, and marketplace development. Alvarez began his career with Arthur Andersen Consulting, then went on to earn his MBA at Harvard.
Henry Goh, VP of APAC Sales: Goh will be leading all APAC sales as the VP of Sales, APAC. For the past 10 years, Goh has been running APAC sales for Ariba. Prior to Ariba, he was at PwC and Oracle leading teams across Asia. Goh has a wealth of experience in “go-to-market” strategy in APAC. He has experience in large deal negotiations including cultivating, developing, formulating and constructing deals.
Raphael Bres, Chief Product Officer: Bres brings to Tradeshift over 20 years experience building ERP’s at Workday, FinancialForce, and Peoplesoft, built on a solid foundation from Deloitte, Oracle and Microsoft. While Bres will be based out of our San Francisco office, he also brings strong global experience, having not only held international roles but also earning his graduate degrees from Université Paris Dauphine.
“This is a pivotal year for Tradeshift and we’re hyper-focused on the areas of the business that will give us the greatest momentum and lead us to profitability,” said Christian Lanng, CEO of Tradeshift. “With a combined 70 years of experience, Janet, Tony, Henry and Raphael will successfully lead the charge on tackling the aggressive and ambitious goals we have set out for ourselves and will no doubt make this the most successful year we’ve seen at Tradeshift.”
About Tradeshift
Tradeshift drives supply chain innovation for the digitally connected economy. As the leader in supply chain payments and marketplaces, the company helps buyers and suppliers digitize all their trade transactions, collaborate on every process, and connect with any supply chain app. More than 1.5 million companies across 190 countries trust Tradeshift to process over half a trillion USD in transaction value, making it the largest global business network for buying and selling. Discover commerce for all at tradeshift.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200210005298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom